Published in J Clin Gastroenterol on January 01, 2013
Venous thromboembolism after surgery for inflammatory bowel disease: are there modifiable risk factors? Data from ACS NSQIP. Dis Colon Rectum (2012) 1.06
Quality improvement in inflammatory bowel disease. Gastroenterol Hepatol (N Y) (2013) 1.00
Physicians' perceptions of risks and practices in venous thromboembolism prophylaxis in inflammatory bowel disease. Dig Dis Sci (2012) 0.98
Inflammatory bowel disease and thromboembolism. World J Gastroenterol (2014) 0.97
Venous thromboembolism in patients with inflammatory bowel disease: focus on prevention and treatment. World J Gastroenterol (2014) 0.86
Thromboprophylaxis is associated with reduced post-hospitalization venous thromboembolic events in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol (2014) 0.82
Opportunities for Improvement in the Care of Patients Hospitalized for Inflammatory Bowel Disease-Related Colitis. Dig Dis Sci (2016) 0.80
Sedation in French intensive care units: a survey of clinical practice. Ann Intensive Care (2013) 0.76
Colectomy is a risk factor for venous thromboembolism in ulcerative colitis. World J Gastroenterol (2015) 0.76
Quality of care in inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2(nd) Asian Organization of Crohn's and Colitis (AOCC) meeting in Seoul. Intest Res (2016) 0.75
Physician perceptions on colonoscopy quality: results of a national survey of gastroenterologists. Gastroenterol Res Pract (2014) 0.75
Thromboembolic events in patients with inflammatory bowel disease. Saudi J Gastroenterol (2016) 0.75
Changes in cardiac arrest patients' temperature management after the 2013 "TTM" trial: results from an international survey. Ann Intensive Care (2016) 0.75
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol (2012) 5.66
Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol (2010) 5.20
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75
Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med (2012) 4.41
Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med (2013) 3.98
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology (2009) 3.73
Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol (2004) 3.63
Possible association between isotretinoin and inflammatory bowel disease. Am J Gastroenterol (2006) 2.97
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology (2011) 2.96
Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol (2006) 2.88
Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol (2009) 2.72
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology (2007) 2.55
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol (2008) 2.16
AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology (2010) 2.09
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology (2005) 2.05
Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol (2011) 2.04
LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol (2010) 1.85
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut (2011) 1.80
The risk of developing Crohn's disease after an appendectomy: a meta-analysis. Am J Gastroenterol (2008) 1.74
Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology (2007) 1.71
Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut (2011) 1.70
Appendiceal mucinous cystadenoma is a neoplastic complication of IBD: case-control study of primary appendiceal neoplasms. Inflamm Bowel Dis (2009) 1.69
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology (2007) 1.60
Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm Bowel Dis (2006) 1.58
Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology (2008) 1.56
Are pANCA, ASCA, or cytokine gene polymorphisms associated with pouchitis? Long-term follow-up in 102 ulcerative colitis patients. Am J Gastroenterol (2004) 1.50
Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. Inflamm Bowel Dis (2010) 1.42
An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol (2011) 1.42
Bacterial-metal interactions: the potential role of aluminum and other trace elements in the etiology of Crohn's disease. Inflamm Bowel Dis (2004) 1.42
Is there physician bias against eliciting affective qualities of pain? J Clin Gastroenterol (2010) 1.40
The effect of intravenous cyclosporine on rates of colonic surgery in hospitalized patients with severe Crohn's colitis. J Clin Gastroenterol (2012) 1.38
Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis (2013) 1.33
Occurrence of colon ischemia in relation to irritable bowel syndrome. Am J Gastroenterol (2004) 1.25
Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol (2011) 1.24
Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol (2012) 1.23
Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis (2011) 1.22
Transition of adolescents with inflammatory bowel disease from pediatric to adult care: a survey of adult gastroenterologists. J Pediatr Gastroenterol Nutr (2009) 1.22
A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol (2012) 1.22
Outcome of surgical versus percutaneous drainage of abdominal and pelvic abscesses in Crohn's disease. Am J Gastroenterol (2006) 1.21
The inflammatory bowel diseases and ambient air pollution: a novel association. Am J Gastroenterol (2010) 1.19
Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis (2010) 1.15
Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology (2012) 1.15
5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis (2007) 1.14
IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010--Inflammatory Bowel Disease Task Force meeting. Inflamm Bowel Dis (2011) 1.14
Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology (2013) 1.14
Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal (2008) 1.13
Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.13
Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management. J Manag Care Pharm (2010) 1.11
Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis (2008) 1.09
Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg (2008) 1.09
Risk factors for colorectal cancer in Crohn's colitis: a case-control study. Inflamm Bowel Dis (2006) 1.05
Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials? Inflamm Bowel Dis (2012) 1.00
Acute appendicitis following colonoscopy. J Clin Gastroenterol (2005) 1.00
Risk factors for colon ischemia. Am J Gastroenterol (2004) 1.00
A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis (2006) 0.99
State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis (2005) 0.98
Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut (2011) 0.97
Are your patients taking their medicine? Validation of a new adherence scale in patients with inflammatory bowel disease and comparison with physician perception of adherence. Inflamm Bowel Dis (2011) 0.97
Small bowel adenocarcinoma in Crohn's disease. J Gastrointest Surg (2011) 0.96
Current practice and perception of screening for medication adherence in inflammatory bowel disease. J Clin Gastroenterol (2011) 0.96
The risk of developing Crohn's disease after an appendectomy: a population-based cohort study in Sweden and Denmark. Gut (2007) 0.96
Adenocarcinoma following ileal pouch-anal anastomosis for ulcerative colitis: review of 26 cases. Inflamm Bowel Dis (2009) 0.94
Colorectal carcinoma in indeterminate colitis. Inflamm Bowel Dis (2009) 0.94
When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. Inflamm Bowel Dis (2010) 0.93
Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride. Am J Gastroenterol (2003) 0.92
Selective leukocyte apheresis for the treatment of inflammatory bowel disease. J Clin Gastroenterol (2007) 0.92
Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species. Antimicrob Agents Chemother (2003) 0.92
Segmental colitis associated with diverticular disease and other IBD look-alikes. J Clin Gastroenterol (2006) 0.90
Altered terminal glycosylation and the pathophysiology of CF lung disease. J Cyst Fibros (2004) 0.90
Improving quality of care in IBD: a STEEEP challenge. Inflamm Bowel Dis (2010) 0.90
Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflamm Bowel Dis (2011) 0.89
Granulomatous enterocolitis associated with Hermansky-Pudlak syndrome. Am J Gastroenterol (2006) 0.89
Rates of pharmacologic venous thromboembolism prophylaxis in hospitalized patients with active ulcerative colitis: results from a tertiary care center. J Crohns Colitis (2013) 0.86
Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis (2011) 0.86
Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model. Clin Gastroenterol Hepatol (2011) 0.85
Chemoprevention of colorectal cancer in ulcerative colitis. Int J Colorectal Dis (2003) 0.85
Validation of interactive voice response system administration of the Short Inflammatory Bowel Disease Questionnaire. Inflamm Bowel Dis (2009) 0.85
Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease. Am J Gastroenterol (2008) 0.85
Severity of inflammation as a predictor of colectomy in patients with chronic ulcerative colitis. Dis Colon Rectum (2009) 0.85
Genomics and phenomics in Crohn's disease. Gastroenterology (2002) 0.84
Farnesoid X receptor expression is decreased in colonic mucosa of patients with primary sclerosing cholangitis and colitis-associated neoplasia. Inflamm Bowel Dis (2013) 0.84
Early readmission in patients hospitalized for ulcerative colitis: incidence and risk factors. Scand J Gastroenterol (2015) 0.84
Challenges in designing a national surveillance program for inflammatory bowel disease in the United States. Inflamm Bowel Dis (2014) 0.83
The management of immunosuppression in patients with inflammatory bowel disease and cancer. Gut (2013) 0.83
Efficacy of methotrexate in ulcerative colitis: failure or promise. Inflamm Bowel Dis (2010) 0.83
Effects of growth hormone secretion on body composition in patients with Crohn's disease. J Clin Endocrinol Metab (2003) 0.82
Innate immune receptor genetic polymorphisms in pouchitis: is CARD15 a susceptibility factor? Inflamm Bowel Dis (2005) 0.82
Immediate versus tailored prophylaxis to prevent symptomatic recurrences after surgery for ileocecal Crohn's disease? Surgery (2011) 0.81
Menstrual cycle changes in women with inflammatory bowel disease: a study from the ocean state Crohn's and colitis area registry. Inflamm Bowel Dis (2014) 0.80
Genetics, Genetic Testing, and Biomarkers of Digestive Diseases. Gastroenterology (2015) 0.80
Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis (2013) 0.80
Serum Proteome Profiles in Stricturing Crohn's Disease: A Pilot Study. Inflamm Bowel Dis (2015) 0.80